Supernus Announces Issuance of Third US Patent Protecting Trokendi XR™
12 March 2014 - 10:30PM
Business Wire
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced the issuance of a third patent (number 8,663,683)
by the United States Patent and Trademark Office (USPTO) covering
Trokendi XR™, its novel once-daily extended-release topiramate
product. The patent was issued by the USPTO on March 04, 2014. It
provides protection for the product with expiration that is no
earlier than 2027.
“We continue to place great importance on expanding and
protecting our intellectual property to ensure the sustainability
and longevity of our products. The issuance of this patent provides
us with a broadened proprietary position with respect to our
extended release formulation of topiramate. We now have patent
protection on Oxtellar XR® and Trokendi XR™ through three issued
U.S. patents each, and are focused on further expanding such
protection,” said Jack A. Khattar, President and CEO of
Supernus.
Supernus has several additional patent applications for
extended-release topiramate and extended-release oxcarbazepine
pending in other geographic regions.
About Trokendi XR™
Trokendi XR is the only approved novel once-daily extended
release formulation of topiramate for the treatment of epilepsy.
Trokendi XR is an antiepileptic drug indicated for initial
monotherapy in patients 10 years of age and older with partial
onset or primary generalized tonic-clonic seizures; adjunctive
therapy in patients 6 years of age and older with partial onset or
primary generalized tonic-clonic seizures; and adjunctive therapy
in patients 6 years of age and older with seizures associated with
Lennox-Gastaut syndrome. The product is available in 25mg, 50mg,
100mg and 200mg extended-release capsules.
For full prescribing and safety
information, click here.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The Company
has two marketed products for epilepsy, Oxtellar XR®
(extended-release oxcarbazepine) and Trokendi XR™ (extended-release
topiramate). The Company is also developing several product
candidates in psychiatry to address large market opportunities in
ADHD, including ADHD patients with impulsive aggression. These
product candidates include SPN-810 for impulsive aggression in ADHD
and SPN-812 for ADHD.
Forward Looking Statements
This press release contains forward-looking statements regarding
the potential of Trokendi XR and Oxtellar XR and intellectual
property protection. Actual results may differ materially from
those in these forward-looking statements as a result of various
factors, including, but not limited to, risks regarding the
company's ability to commercialize the product successfully,
whether physicians will prescribe and patients will use the
product, and competition in the market. For a further description
of these and other risks facing the Company, please see the risk
factors described in the Company's Annual Report Form 10-K that was
filed with the United States Securities and Exchange Commission on
March 15, 2013 and under the caption "Risk Factors" and the updates
to these risk factors in the Company's quarterly report form 10-Q
that was filed with the Commission on August 14, 2013.
Forward-looking statements speak only as of the date of this press
release, and the company undertakes no obligation to update or
revise these statements, except as may be required by law.
Jack A. Khattar, President and CEOGregory S. Patrick, Vice
President and CFOSupernus Pharmaceuticals, Inc.Tel: (301)
838-2591OrINVESTOR CONTACT:COCKRELL
GROUP877.889.1972investorrelations@thecockrellgroup.comcockrellgroup.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2024 to May 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From May 2023 to May 2024